GlassScriptPhysician profile
Heather Hartman
NPI 1558504118
$6,784.56
in general payments reported to CMS, 2019-2025
32 companies · $1,010 in 2025
The $1,010 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $529 · 2020: $249 · 2021: $1,044 · 2022: $1,096 · 2023: $1,461 · 2024: $1,396 · 2025: $1,010.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,866 · Education: $1.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,865.93 |
| Education | $1.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,385.93 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Genzyme Corporation | $868.43 | 2020-2025 | |
| Astrazeneca Pharmaceuticals LP | $824.38 | 2019-2025 | Fasenra, Airsupra |
| Takeda Pharmaceuticals U.S.A., INC. | $689.24 | 2020-2025 | Cuvitru, Takhzyro |
| Genentech USA, INC. | $331.16 | 2021-2025 | Xolair |
| Csl Behring | $263.72 | 2020-2025 | Andembry, Privigen, Hizentra |
| Pfizer INC. | $240.96 | 2019-2025 | |
| Grifols USA, LLC | $210.73 | 2023-2024 | Prolastin-C Liquid, Xembify |
| Blueprint Medicines Corporation | $194.38 | 2023-2025 | Ayvakit |
| Abbvie INC. | $192.42 | 2022-2023 | |
| Biocryst US Sales Co., LLC | $184.91 | 2021-2025 | Orladeyo |
| Optinose US, INC. | $177.90 | 2019-2024 | |
| Verona Pharma, INC. | $165.15 | 2025 | Ohtuvayre |
| Regeneron Healthcare Solutions, INC. | $147.08 | 2019 | |
| Alk-Abello, INC | $129.90 | 2021-2024 | Grastek, Ragwitek, Odactra |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $109.06 | 2021-2022 | |
| Aimmune Therapeutics, INC. | $105.07 | 2022 | |
| Covis Pharma Gmbh | $74.14 | 2021-2022 | |
| Kaleo, INC. | $72.24 | 2021-2023 | Auvi-Q |
| Boehringer Ingelheim Pharmaceuticals, INC. | $61.07 | 2021-2022 | |
| Hikma Pharmaceuticals USA | $57.48 | 2023-2025 | Ryaltris |
| Amgen INC. | $57.17 | 2022-2024 | Tezspire |
| Novartis Pharmaceuticals Corporation | $56.69 | 2019-2025 | |
| Adma Biomanufacturing LLC | $50.02 | 2021-2022 | |
| Biomerieux INC | $19.90 | 2025 | |
| Hospira, INC. | $19.43 | 2025 | |
| Ars Pharmaceuticals Operations, INC. | $18.79 | 2025 | Neffy |
| Octapharma USA, INC. | $17.66 | 2023 | Cutaquig |
| Horizon Therapeutics Plc | $15.96 | 2021 | |
| Leo Pharma INC. | $14.92 | 2022 | |
| Eyevance Pharmaceuticals LLC | $14.55 | 2021 | |
| Pharming Healthcare, INC. | $14.12 | 2025 | Ruconest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Hartman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.